Purchase Order HT942525P0019

This is a Firm Fixed Price contract awarded by the Defense Health Agency to Hexamer Therapeutics Inc., a self-certified small disadvantaged business, for $3,928,061.02. The contract is for research and development services related to a self-assembling vaccine platform, under a Broad Agency Announcement issued by the U.S. Army Medical Research and Development Command. The contract has an ultimate completion date of November 28, 2025 and was awarded on September 29, 2023. The original solicitation...

This is a $600,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to develop an effective human immunodeficiency virus (HIV) vaccine using engineered nanoparticles loaded with messenger RNA (mRNA) targeted to antigen presenting cells. This contract is part of the Small Business Innovation Research (SBIR)...

<p>This is a $149,710.00 firm fixed-price purchase order awarded by the Defense Logistics Agency Headquarters to Graphenix Development, Inc., a self-certified small disadvantaged business and manufacturer of goods. The contract is for a 12-month base period of performance under the SBIR (Small Business Innovation Research) Phase I program. The place of performance is Fort Belvoir, Virginia. The award was made on May 27, 2021, with a completion date of May 26, 2022.</p>

<p>This is a $249,723.49 firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Solaris Vaccines, Inc. under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the development of a &quot;VACCIRAPTOR: HIGH-THROUGHPUT, CONTINUOUS FLOW-THROUGH DEVICE FOR PSORALEN-UVA INACTIVATION OF DENGUE VIRUS.&quot; The contract has a total small business set-aside and an ultimate completion date of January 20, 2025.</p>

<p>This is a $1,999,175.53 firm fixed-price Definitive Contract awarded by the Defense Health Agency (DHA), a defense agency, to Technovax Inc., a small disadvantaged business, under the SBIR (Small Business Innovation Research) Phase II program. The contract is for research and development work, with a period of performance ending on February 16, 2021. The contract was set aside for small businesses.</p>

This is a $299,999.00 Firm Fixed Price Definitive Contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Luna Innovations Incorporated, a small business manufacturer, for the CNT-VECTORED DELIVERY OF MRNA FOR HIV-VACCINES research project under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the development and delivery of products and services related to this...

<p>This is a $230,867.83 firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Sunfire Biotechnologies LLC, a minority-owned, self-certified small disadvantaged business. The contract is for medical research and development under the DHA's Small Business Innovation Research (SBIR) Phase I program. The contract is set aside for small businesses and has an August 31, 2021 completion date.</p>

This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research...

This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...

This task order funds the guaranteed minimum amount under a preexisting master indefinite-delivery/indefinite-quantity contract between the National Institutes of Health's National Institute of Allergy and Infectious Diseases and Advanced Bioscience Laboratories, Inc. The purpose is to support preclinical and translational vaccine development for HIV and other candidate agents. The $2,500 delivery order was awarded on December 1, 2021 with a one-year period of performance ending November 30,...